iShares Trust iShares iBonds Dec 2032 Term Corporate ETF (ARCA: IBDX)

에 대한 최신 뉴스 iShares Trust iShares iBonds Dec 2032 Term Corporate ETF (ARCA:IBDX)

The Fund seeks to meet its investment objective generally by investing in component securities of the Bloomberg December 2032 Maturity Corporate Index (the Underlying Index). Fund will invest at least 90% of its assets in fixed income securities of the types included in the Underlying Index that BFA believes will help the Fund track the Underlying Index. The Fund will invest no more than 10% of its assets in futures, options and swaps contracts that BFA believes will help the Fund track the Underlying Index as well as in fixed income securities other than the types included in the Underlying Index

iShares iBonds Dec 2032 Term Corporate ETF

iShares Trust iShares iBonds Dec 2032 Term Corporate ETF

LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.38) by 65.79 percent. This is a 550 percent decrease over losses of $(0.02) per share from the same period last year.

Earnings

Earnings Beats

News

LVTX

LAVA Therapeutics Q1 EPS $(0.13) Beats $(0.38) Estimate

Needham analyst Mike Matson upgrades Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) from Hold to Buy and announces $48 price target.

Upgrades

Price Target

Analyst Ratings

ESTA

Needham Upgrades Establishment Labs Hldgs to Buy, Announces $48 Price Target

Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) has surged 65% over the past month, sharply outperforming other digital assets after a prolonged stretch of <a href="https://www.benzinga.com/money/btc-vs-eth">underperformance relative to Bitcoin</a>.
What Happened: According to a new report by Bernstein on Wednesday, the rebound is being driven by a convergence of structural and tactical catalysts.
The rally, they argue, is underpinned by three primary trends: renewed focus on blockchain utility via stablecoins, rising institutional interest in Ethereum's Layer 2 ecosystems and a major unwind of bearish hedge fund positioning.
"Stablecoins are bringing back the focus on underlying blockchain networks becoming platform proxies to gain exposure to the growth trend," the report said. 
Ethereum currently accounts for 51% of minted stablecoin supply, making it a key infrastructure layer for this segment.
The second catalyst revolves around the Layer 2 chains built on Ethereum. 
"Layer 2 chains use ETH for gas fees as underlying currency, thus helping drive distribution and demand for ETH," Bernstein noted, pointing to Base's $85 million in annual sequencer fees and Robinhood's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) recent acquisition of WonderFi as indicators of broader adoption. 
Also Read: <a href="https://www.benzinga.com/markets/25/05/45388118/bitcoin-taps-105-000-heres-when-it-could-hit-122-000">Bitcoin Taps $105,000: Here&#8217;s When It Could Hit $122,000</a>
This model, Bernstein says, "might become the template for asset managers and institutional users launching their own layer 2 chain on Ethereum."
Lastly, the report highlights a more tactical reason for Ethereum's strength: a repositioning among crypto hedge funds. 
"For the last 12-18 months, ETH was the perfect delta-neutral hedge. Crypto hedge funds were long Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) and short ETH," the analysts wrote.
What&#8217;s Next: As the narrative now shifts toward blockchain utility and institutional adoption, these shorts are being closed.
The broader implication of Ethereum's rally is also positive for the digital asset ecosystem at large. 
"Resurgence of ETH and non-Bitcoin assets is also good for crypto exchanges and broker-dealers, as a broader crypto market rally reinvigorates retail traders," Bernstein said.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45387228/can-the-us-china-tariff-de-escalation-send-bitcoin-ethereum-to-new-highs">Can The US-China Tariff De-Escalation Send Bitcoin, Ethereum To New Highs?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

HOOD

3 Key Drivers Behind Ethereum's 65% Rally: Bernstein

Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 27.27 percent increase over losses of $(0.22) per share from the same period last year.

GANX

Gain Therapeutics Q1 EPS $(0.16) Beats $(0.18) Estimate

Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) affirms FY2025 sales outlook from $380.00 million to $380.00 million vs $389.93 million estimate.

Guidance

NEXN

Nexxen International Affirms FY2025 Contribution ex-TAC of approximately $380 million

AFC Gamma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) reported quarterly earnings of $0.21 per share which missed the analyst consensus estimate of $0.25 by 16 percent. This is a 57.14 percent decrease over earnings of $0.49 per share from the same period last year.

Earnings Misses

AFCG

AFC Gamma Q1 Adj. EPS $0.21 Misses $0.25 Estimate

WIIM

KRMN

Karman Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

CLBT

Cellebrite DI shares are trading lower after the company reported mixed Q1 financial results and cut its FY25 sales guidance with its midpoint below estimates. Also, the company issued Q2 sales guidance with its midpoint below estimates.

Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 30 percent. This is a 30 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $1.76 million which missed the analyst consensus estimate of $1.78 million by 0.84 percent. This is a 15.14 percent increase over sales of $1.53 million the same period last year.

ABUS

Arbutus Biopharma Q1 EPS $(0.13) Misses $(0.10) Estimate, Sales $1.76M Miss $1.78M Estimate

Needham analyst Gil Blum reiterates Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy and maintains $9 price target.

Reiteration

ABSI

Needham Reiterates Buy on Absci, Maintains $9 Price Target

Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.05 by 220 percent. This is a 700 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $78.33 million which beat the analyst consensus estimate of $76.60 million by 2.26 percent. This is a 5.24 percent increase over sales of $74.43 million the same period last year.

Nexxen International Q1 Adj. EPS $0.16 Beats $0.05 Estimate, Sales $78.33M Beat $76.60M Estimate

Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 15.79 percent decrease over losses of $(0.38) per share from the same period last year.

INZY

Inozyme Pharma Q1 EPS $(0.44) Misses $(0.41) Estimate

Pony AI Inc. ("Pony.ai" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>), a global leader in achieving large-scale commercialization of autonomous mobility, today announced that Dr. Jun Peng, Chairman of the Board, Co-founder, and CEO, and Dr. Tiancheng Lou, Co-founder and CTO, have each entered into voluntary extended lock-up agreements (the "Extended Lock-Ups"). These agreements cover all shares of the Company's share capital or securities convertible into, exchangeable, or exercisable for any shares of the Company's share capital directly or indirectly owned by the co-founders for a period of 540 days starting from May 25, 2025, the expiration date of the Company's initial public offering lock-up period.
The Extended Lock-Ups cover a total of 110,828 Class A ordinary shares and 81,088,770 Class B ordinary shares, representing approximately 22.9% of the Company's total issued and outstanding ordinary shares as of the date of this announcement.

PONY

Pony.ai Co-Founders Extend Lock-Up on Nearly 23% of Shares, Signaling Long-Term Commitment

Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) with a Buy and lowers the price target from $38 to $35.

MGTX

Chardan Capital Maintains Buy on MeiraGTx Hldgs, Lowers Price Target to $35

Wedbush analyst Daniel Ives praised the upcoming &#8216;AI Revolution&#8217; in Saudi Arabia and the Middle East after the U.S.-Saudi Investment Forum on Tuesday, which saw a slew of announcements on the artificial intelligence front.
What Happened: The Jensen Huang-led chipmaker announced a new agreement to supply 18,000 GB300 <a href="https://www.benzinga.com/markets/25/05/45397196/jensen-huangs-wealth-surges-37-since-liberation-day-lows-as-nvidia-re-enters-3-trillion-market-cap-club-on-saudi-chip-pact">Blackwell chips</a> to Saudi-based AI startup Humain, backed by the nation's sovereign wealth fund.
Ives said in a series of X posts that &#8220;the AI Revolution is coming to the Saudi Kingdom and Riyadh will be a major buyer of AI chips, software, autonomous/robotics, datacenters over the next decade.&#8221;
He also added that this move will be bullish for firms like, Nvidia, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
&#8220;Bullish for Nvidia, Tesla, Palantir, Microsoft, Alphabet, Amazon. Just starting,&#8221; he added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The theme was clear in Riyadh&#8230;the AI Revolution is coming to the Saudi Kingdom and Riyadh will be a major buyer of AI chips, software, autonomous/robotics, datacenters over the next decade. Bullish for Nvidia, Tesla, Palantir, Microsoft, Alphabet, Amazon. Just starting &#x1f3c6;&#x1f525;&#x1f402;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1922591983027020045?ref_src=twsrc%5Etfw">May 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He added that this was a part of President Donald Trump&#8216;s administration&#8217;s &#8220;global game of high stakes poker&#8221;. He highlighted the curbs on China to acquire Nvidia&#8217;s chips and how the U.S. was steering toward giving Saudi Arabia to supply its next generation chips.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It also speaks to this global game of high stakes poker being played by the Trump Admin as while China is getting blockades from Nvidia&#39;s older H20 chip slowing down the AI buildout in Beijing, on the contrary Saudi getting the best Nvidia next generation chips red carpet rollout <a href="https://t.co/ALaTBIozUX">https://t.co/ALaTBIozUX</a>
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1922604976020320432?ref_src=twsrc%5Etfw">May 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;This is all part of a regional focus in the Middle East building out datacenters and the AI Revolution which will start to vault UAE, Saudi, Qatar to the priority list for US tech companies. Adds major TAM to AI Revolution,&#8221; he said.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest">Warren Buffett Shows How Patience Pays: 98% Of His $160 Billion Wealth Came After Turning 65, Thanks The Power Of &#8216;Compound Interest&#8217;</a>
Why It Matters: Following a dip to $83 billion in the first week of April, shortly after the &#8220;Liberation Day&#8221; tariffs, Huang&#8217;s net worth has since experienced a <a href="https://www.benzinga.com/markets/25/05/45397196/jensen-huangs-wealth-surges-37-since-liberation-day-lows-as-nvidia-re-enters-3-trillion-market-cap-club-on-saudi-chip-pact">significant rebound</a>. By the end of Tuesday, it had surged by 37% from that low point, reaching just under $120 billion. &#8211;
Also, Nvidia's recent stock rally has driven the company back into the $3 trillion market cap club.
Meanwhile, Trump also <a href="https://www.benzinga.com/markets/equities/25/05/45398595/trump-praises-nvidia-ceo-jensen-huang-at-saudi-summit-tim-cook-isnt-here-but-you-are-controlling-99-of-the-chip-market-thats-not-easy-to-beat">appreciated Huang</a> at the Forum and said, "I see my friend is here, Jensen. [Apple Inc. CEO] Tim Cook isn't here, but you are.&#8221;
"What a job you've done. He's got 99% of the chip market. That's not easy to beat,&#8221; he added.
"Thank you for the investment. We are proud to have you in our country," Trump told Huang.
Price Action: Shares of Nvidia rose 5.63% on Tuesday and were up 2.61% on Wednesday in pre-market trading. However, the stock was down 6.06% on a year-to-date basis and up 42.22% over a year.
Benzinga Edge Stock Rankings shows that NVDA had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid at 82.75th percentile, whereas its value ranking was poor at 6.65th percentile; the details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>. 
<figure class="wp-block-image size-large"><a href=" https://www.benzinga.com/quote/NVDA"><img loading="lazy" decoding="async" width="1024" height="143" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14071534/EDGE-NVDA-1024x143.png" alt="" class="wp-image-914799" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14071534/EDGE-NVDA-1024x143.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14071534/EDGE-NVDA-300x42.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14071534/EDGE-NVDA-768x108.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14071534/EDGE-NVDA.png 1228w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Wednesday. The SPY was up 0.16% to $587.79, while the QQQ advanced 0.33% to $517.30, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pr</a>o data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45399288/kevin-oleary-lauds-robinhoods-acquisition-of-wonderfi-will-transform-cross-border-trading-no-more-outrageous-bank-fees">Kevin O&#8217;Leary Lauds Robinhood&#8217;s Acquisition Of WonderFi Will &#8216;Transform Cross-Border Trading:&#8217; &#8216;No More Outrageous Bank Fees&#8217;</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Government

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Markets

Tech

ETFs

General

AMZN

GOOG

GOOGL

MSFT

PLTR

TSLA

'Bullish For Nvidia, Tesla, Palantir, Microsoft, Alphabet, Amazon:' AI 'Revolution Is Coming' To The Saudi Kingdom, Says Wedbush's Dan Ives

Owens Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>), a building products leader, today announced that its Board of Directors has approved a new share repurchase authorization for up to 12 million shares of the company's common stock. The action reaffirms the company's capital allocation strategy and reflects the success of its disciplined commercial and operational execution to deliver consistent and sustainable performance in dynamic market conditions.
This authorization is in addition to the previously announced share repurchase program in which approximately 5.7 million shares remained available for repurchase as of March 31, 2025.

Owens Corning Board Approves New Share Repurchase Authorization For Up To 12M Shares

Biotech

ABEO

Abeona Therapeutics And Lurie Children's Open Center For ZEVASKYNTM Gene Therapy To Treat Wounds Associated With Recessive Dystrophic Epidermolysis Bullosa

PDSB

PDS Biotechnology Q1 EPS $(0.21) Beats $(0.25) Estimate

Quoin Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) (the "Company" or "Quoin"), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive initial clinical data from its ongoing Investigator Pediatric Peeling Skin Syndrome clinical study.
As the table below illustrates, after 12 weeks of treatment, clear evidence of skin healing in the area treated with QRX003 compared to baseline was observed.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>End Point</td>
<td>Baseline</td>
<td>12 weeks (End of treatment period) &nbsp;</td>
</tr>
<tr>
<td>M-IASI&#x2A;</td>
<td>36</td>
<td>12 &nbsp;</td>
</tr>
<tr>
<td>IGA&#x2A;&#x2A;</td>
<td>4 (Severe)</td>
<td>2 (Mild) &nbsp;</td>
</tr>
<tr>
<td>CDQLI&#x2A;&#x2A;&#x2A;</td>
<td>19</td>
<td>11 &nbsp;</td>
</tr>
</tbody>
</table>
</figure>
 &#x2A;M-IASI: Modified Ichthyosis Area of Severity Index, a score used to assess the severity and extent of skin symptoms associated with ichthyosis. Lower scores indicate improvement. &#x2A;&#x2A;IGA: Investigator's Global Assessment, which uses descriptive categories (e.g., clear, mild, moderate, severe) to evaluate the overall severity of disease symptoms.
&#x2A;&#x2A;&#x2A; CDQLI: The Children's Dermatology Life Quality Index is a validated clinical tool designed for children aged 4-15 that is used to measure the impact of their skin disease on a child's quality of life in terms of symptoms, leisure activities, sleep, school, personal relationship and treatment. The scale for the CDQLI is 0-30.
QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial results, the patient is expected to continue to be treated with QRX003 with a further clinical assessment by the investigator scheduled after 24 weeks of treatment.

QNRX

Quoin Reports Early Data for Rare Skin Disease Treatment With No Adverse Events

Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.13 by 46.15 percent. This is a 50 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $1.08 billion which beat the analyst consensus estimate of $1.05 billion by 2.14 percent. This is a 0.41 percent decrease over sales of $1.08 billion the same period last year.

Comments

iShares Trust iShares iBonds Dec 2032 Term Corporate ETF

뉴스

에 대한 최신 뉴스 iShares Trust iShares iBonds Dec 2032 Term Corporate ETF (ARCA:IBDX)

뉴스

파트너 / 기고자

벤징가 글로벌